- Email: [email protected]
Diet in oncology according to traditional Chinese medicine and homeopathy
Poster Presentations / European Journal of Integrative Medicine 4S (2012) 124–201
PP-021 Diet in oncology according to traditional Chinese medicine and homeopathy Traversi Antonella, Segantini Sergio, Niccoli Barbara, Cucca Barbara, Baccetti Sonia Fior di Prugna Referral Center for Complementary Medicine of Tuscany Region, S. Donnino - Campi Bisenzio (Florence), Italy Background: In the patient affected by an oncologic disease, there is often a condition of general decline of nutritional state related to the disease, lack of appetite and digestive disorders, often related to the side effects of the therapy. The consequence is a decrease of the immune resistance and of the ability of the body to fight the cancer. Traditional Chinese medicine (TCM) states that “diet and drugs can be used in the same way,” as they have the same therapeutic value. Food can help to create energy, contributes to a good functioning of the body and also to psychic wellness and, therefore, it improves the quality of life. Recent studies of Western medicine confirm that the quality of food can interfere with the progression of the illness. Food can be used differently by the various schools and therapeutic techniques. Aim: As a model of integrative treatment in oncology is applied in public clinics of Tuscany also in the nutritional area, the aim of this study was to examine the different approaches to providing homogeneous advice to oncologic patients. Results: TCM, homeopathy and also part of the Western medicine agree that food plays a relevant role in health and that it is important how it is cooked and to pay a greater attention to its energy characteristics. Among the good rules that facilitate a good digestion and the absorption of the energy, there is advice to eat moderately in a state of tranquillity, and chewi the food carefully for a long time. The fundamental concepts of the traditional Chinese diet and homeopathy are described, with their correlations with the nature, shape and colour of the food. Recommendations are made regarding the food and drinks that oncologic patients should consume, namely organic and fresh food rich in ‘jing’ (energy and nutritional value), possibly harvested when it is completely and naturally ripe and not cooked too long. Food and drinks with specific anticancer activity, according to the international literature are also reported.
133
(IO). It aims to improve patients’ health-related quality of life and draws on patients’ salutogenic resources. Aim: In the present study, we characterise the use of ET in patients from a clinical registry with a particular emphasis on IO. Methods: A total of 10 405 patients are documented in Network Oncology (NO), a joint clinical registry of German hospitals and out-patient facilities. We used the non-parametric Fisher exact test (F) to compare observed frequencies and the Wilcoxon rank sum (W) test for differences between groups. A logistic regression model was used to explain use of ET. Results: Forty-six percent of the NO patients received ET, of which 82% were female. Female ET patients were younger than male (med♀ = 55, med♂ = 61, W = 2039955, p < 0.001). There was no significant difference in the frequency of cancer entities between ET patients who did and those who did not receive ET. Over all International Union Against Cancer (UICC) stages were 0: 3.5%, I: 23.4%, II: 30.9%, III: 20% and IV: 22.3%, and no significant difference was observed compared to non-ET patients. Eighty-nine percent of the ET patients had surgery, 52% received chemotherapy and 37% radion therapy. No significant difference was found in the frequency of conventional therapies compared to the group that received no ET (74%, 48% and 31%). Ninety-three percent received additional mistletoe therapy and again no significant difference was observed compared to non-ET patients (81%). Use of additional NMIs was significantly higher in ET patients than in patients who received another NMI but no ET (medCE = 5, medother NMI = 2, W = 7506537, p < 0.001). Male gender, increasing age and chemotherapy were negatively (age = –0.025, male = –0.607, chemo = –0.455, all p < 0.001) associated with getting ET, whereas surgery was positively associated with ET (surgery = 0.404, p = 0.001). Conclusions: ET is common in IO settings of anthroposophic medicine and meets patient preference. In line with other studies, females are younger and use ET more often than men. ET is used in addition to other complementary therapies especially after surgery. The high case numbers in NO suggest that a detailed monitoring of integrative therapies is possible. Thus, health service research data can provide a solid basis for prospective studies on outcome-related research in IO. http://dx.doi.org/10.1016/j.eujim.2012.07.782
http://dx.doi.org/10.1016/j.eujim.2012.07.781
PP-023
PP-022 Eurythmy therapy in oncological patients in a Network of Integrative Oncology Schad Friedemann 1 , Axtner Matthias 1 , Matthes Harald 2
Jan 1 , Happe
Antje 1 , Kröz
1 Research
Institute Havelhoehe (FIH), Berlin 2 Hospital Havelhoehe, Berlin, Germany Background: Eurythmy therapy (ET) is an anthroposophic movement therapy and a non-pharmacotherapeutic mindfulness-based intervention (NMI) in integrative oncology
Natural-product anti-cancer drug discovery from antimalarials Wade Christine, Duffy Robert, Chang Raymond Institute of East West Medicine, New York, NY, USA Significance: Naturally derived anti-malarials may have anticancer potential, yet no systematic reviews exist describing their potential as anti-cancer agents. Malaria and cancer are discrete in terms of known aetiology and pathology but existing antimalarial agents, especially the quinolines and the sesquiterpene lactones, may possess known anti-cancer properties that could be distinct from or overlap with anti-malarial properties.
PP-021 Diet in oncology according to traditional Chinese medicine and homeopathy Traversi Antonella, Segantini Sergio, Niccoli Barbara, Cucca Barbara, Baccetti Sonia Fior di Prugna Referral Center for Complementary Medicine of Tuscany Region, S. Donnino - Campi Bisenzio (Florence), Italy Background: In the patient affected by an oncologic disease, there is often a condition of general decline of nutritional state related to the disease, lack of appetite and digestive disorders, often related to the side effects of the therapy. The consequence is a decrease of the immune resistance and of the ability of the body to fight the cancer. Traditional Chinese medicine (TCM) states that “diet and drugs can be used in the same way,” as they have the same therapeutic value. Food can help to create energy, contributes to a good functioning of the body and also to psychic wellness and, therefore, it improves the quality of life. Recent studies of Western medicine confirm that the quality of food can interfere with the progression of the illness. Food can be used differently by the various schools and therapeutic techniques. Aim: As a model of integrative treatment in oncology is applied in public clinics of Tuscany also in the nutritional area, the aim of this study was to examine the different approaches to providing homogeneous advice to oncologic patients. Results: TCM, homeopathy and also part of the Western medicine agree that food plays a relevant role in health and that it is important how it is cooked and to pay a greater attention to its energy characteristics. Among the good rules that facilitate a good digestion and the absorption of the energy, there is advice to eat moderately in a state of tranquillity, and chewi the food carefully for a long time. The fundamental concepts of the traditional Chinese diet and homeopathy are described, with their correlations with the nature, shape and colour of the food. Recommendations are made regarding the food and drinks that oncologic patients should consume, namely organic and fresh food rich in ‘jing’ (energy and nutritional value), possibly harvested when it is completely and naturally ripe and not cooked too long. Food and drinks with specific anticancer activity, according to the international literature are also reported.
133
(IO). It aims to improve patients’ health-related quality of life and draws on patients’ salutogenic resources. Aim: In the present study, we characterise the use of ET in patients from a clinical registry with a particular emphasis on IO. Methods: A total of 10 405 patients are documented in Network Oncology (NO), a joint clinical registry of German hospitals and out-patient facilities. We used the non-parametric Fisher exact test (F) to compare observed frequencies and the Wilcoxon rank sum (W) test for differences between groups. A logistic regression model was used to explain use of ET. Results: Forty-six percent of the NO patients received ET, of which 82% were female. Female ET patients were younger than male (med♀ = 55, med♂ = 61, W = 2039955, p < 0.001). There was no significant difference in the frequency of cancer entities between ET patients who did and those who did not receive ET. Over all International Union Against Cancer (UICC) stages were 0: 3.5%, I: 23.4%, II: 30.9%, III: 20% and IV: 22.3%, and no significant difference was observed compared to non-ET patients. Eighty-nine percent of the ET patients had surgery, 52% received chemotherapy and 37% radion therapy. No significant difference was found in the frequency of conventional therapies compared to the group that received no ET (74%, 48% and 31%). Ninety-three percent received additional mistletoe therapy and again no significant difference was observed compared to non-ET patients (81%). Use of additional NMIs was significantly higher in ET patients than in patients who received another NMI but no ET (medCE = 5, medother NMI = 2, W = 7506537, p < 0.001). Male gender, increasing age and chemotherapy were negatively (age = –0.025, male = –0.607, chemo = –0.455, all p < 0.001) associated with getting ET, whereas surgery was positively associated with ET (surgery = 0.404, p = 0.001). Conclusions: ET is common in IO settings of anthroposophic medicine and meets patient preference. In line with other studies, females are younger and use ET more often than men. ET is used in addition to other complementary therapies especially after surgery. The high case numbers in NO suggest that a detailed monitoring of integrative therapies is possible. Thus, health service research data can provide a solid basis for prospective studies on outcome-related research in IO. http://dx.doi.org/10.1016/j.eujim.2012.07.782
http://dx.doi.org/10.1016/j.eujim.2012.07.781
PP-023
PP-022 Eurythmy therapy in oncological patients in a Network of Integrative Oncology Schad Friedemann 1 , Axtner Matthias 1 , Matthes Harald 2
Jan 1 , Happe
Antje 1 , Kröz
1 Research
Institute Havelhoehe (FIH), Berlin 2 Hospital Havelhoehe, Berlin, Germany Background: Eurythmy therapy (ET) is an anthroposophic movement therapy and a non-pharmacotherapeutic mindfulness-based intervention (NMI) in integrative oncology
Natural-product anti-cancer drug discovery from antimalarials Wade Christine, Duffy Robert, Chang Raymond Institute of East West Medicine, New York, NY, USA Significance: Naturally derived anti-malarials may have anticancer potential, yet no systematic reviews exist describing their potential as anti-cancer agents. Malaria and cancer are discrete in terms of known aetiology and pathology but existing antimalarial agents, especially the quinolines and the sesquiterpene lactones, may possess known anti-cancer properties that could be distinct from or overlap with anti-malarial properties.